Want to join the conversation?
$VRTX said that it expects the vast majority of the eligible patients ages 12 and older in the U.S. will initiate treatment with Orkambi by the end of this year. The company expects to deliver quarter to quarter revenue growth for Orkambi beginning in 2Q16 and continuing through the end of 2016 and into 2017.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.